278 related articles for article (PubMed ID: 8269588)
21. Chemosensitivity of resistant colon cancer cell lines to lobaplatin, heptaplatin, and dicycloplatin.
Wei W; Liu Z; Chen X; Bi F
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):702-7. PubMed ID: 24986092
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro.
Harstrick A; Casper J; Guba R; Wilke H; Poliwoda H; Schmoll HJ
Cancer; 1989 Mar; 63(6):1079-83. PubMed ID: 2645036
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo.
Zhou Z; Jiang H; Xia J; Zhang J
Int J Oncol; 2020 Sep; 57(3):697-706. PubMed ID: 32582992
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
25. Lobaplatin: a new antitumour platinum drug.
McKeage MJ
Expert Opin Investig Drugs; 2001 Jan; 10(1):119-28. PubMed ID: 11116285
[TBL] [Abstract][Full Text] [Related]
26. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
Holford J; Sharp SY; Murrer BA; Abrams M; Kelland LR
Br J Cancer; 1998; 77(3):366-73. PubMed ID: 9472630
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Xie CY; Xu YP; Jin W; Lou LG
Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Orr RM; O'Neill CF; Nicolson MC; Barnard CF; Murrer BA; Giandomenico CM; Vollano JF; Harrap KR
Br J Cancer; 1994 Sep; 70(3):415-20. PubMed ID: 8080724
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
McKeage MJ; Abel G; Kelland LR; Harrap KR
Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
[TBL] [Abstract][Full Text] [Related]
30. Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro.
Engel JB; Martens T; Hahne JC; Häusler SF; Krockenberger M; Segerer S; Djakovic A; Meyer S; Dietl J; Wischhusen J; Honig A
Anticancer Drugs; 2012 Apr; 23(4):426-36. PubMed ID: 22314264
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
32. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
33. Lobaplatin inhibits growth of gastric cancer cells by inducing apoptosis.
Yin CY; Lin XL; Tian L; Ye M; Yang XY; Xiao XY
World J Gastroenterol; 2014 Dec; 20(46):17426-33. PubMed ID: 25516654
[TBL] [Abstract][Full Text] [Related]
34. In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and -resistant rat ovarian tumors.
Frühauf S; Zeller WJ
Cancer Chemother Pharmacol; 1991; 27(4):301-7. PubMed ID: 1998986
[TBL] [Abstract][Full Text] [Related]
35. BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.
Manzotti C; Pratesi G; Menta E; Di Domenico R; Cavalletti E; Fiebig HH; Kelland LR; Farrell N; Polizzi D; Supino R; Pezzoni G; Zunino F
Clin Cancer Res; 2000 Jul; 6(7):2626-34. PubMed ID: 10914703
[TBL] [Abstract][Full Text] [Related]
36. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
37. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
[TBL] [Abstract][Full Text] [Related]
38. [The prospect for cisplatin analogs from the experimental standpoint].
Tashiro T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1358-65. PubMed ID: 2543305
[TBL] [Abstract][Full Text] [Related]
39. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.
Perez RP; Perez KM; Handel LM; Hamilton TC
Cancer Chemother Pharmacol; 1992; 29(6):430-4. PubMed ID: 1568285
[TBL] [Abstract][Full Text] [Related]
40. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
